Compare NBY & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | TOI |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Nursing Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 327.6M |
| IPO Year | 2007 | N/A |
| Metric | NBY | TOI |
|---|---|---|
| Price | $0.77 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 11-07-2025 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | $10,302,000.00 | ★ $461,039,000.00 |
| Revenue This Year | $23.91 | $28.51 |
| Revenue Next Year | $32.05 | $25.30 |
| P/E Ratio | $30.13 | ★ N/A |
| Revenue Growth | ★ 390.34 | 21.67 |
| 52 Week Low | $0.46 | $0.60 |
| 52 Week High | $19.95 | $4.88 |
| Indicator | NBY | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 37.34 |
| Support Level | $0.75 | $2.42 |
| Resistance Level | $2.13 | $3.23 |
| Average True Range (ATR) | 0.58 | 0.22 |
| MACD | -0.61 | -0.05 |
| Stochastic Oscillator | 0.26 | 22.31 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.